The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire by Koffi, K. G. et al.
Hindawi Publishing Corporation
Advances in Hematology
Volume 2010, Article ID 268921, 6 pages
doi:10.1155/2010/268921
Clinical Study
TheEffectofImatinibMesylateforNewlyDiagnosedPhiladelphia
Chromosome-Positive, Chronic-Phase Myeloid Leukemiain
Sub-Saharan African Patients: The Experienceof Cˆ ote d’Ivoire
K. G.Kofﬁ, D. C. Nanho, E.N’dathz, P. Kouehion, R. Dissieka, A. Attia,
K. Mozard, A. Tolo, K. Boidy, N. Meit´ e, R. Ayemou, M. Sekongo, N. Tea, andI. Sanogo
Haematology National Teaching Hospital of Abidjan, 21 BP 632, Abidjan 21, Cote d’Ivoire
Correspondence should be addressed to K. G. Koﬃ, guskof1@yahoo.fr
Received 15 April 2010; Revised 26 May 2010; Accepted 5 July 2010
Academic Editor: Stefan Faderl
Copyright © 2010 K. G. Koﬃ et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his
eﬃcacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate
(Glivec)inCˆ oted’IvoirepatientswithnewlydiagnosedChronicMyeloidLeukemia(CML).FromMay2005toSeptember2009,we
treated42patients(40years;range16–69)withPhiladelphiachromosome(Ph+)positiveinchronicphaseCMLwithoralimatinib
mesylate at daily doses of 400 mg. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR)
were evaluated. At a median follow up of 32 (range 7.6–113) months, the CHR rate in our study group was 76%. A major CR was
found in 19 patients (45%) with 17% and 29% complete and partial CR respectively. There were no signiﬁcant diﬀerences in the
incidence of major cytogenetic response by known prognostics factors. Median time to CHR was 8 months (range 0.4–25), and 16
months(range:0.1–36)forCR.Projected5-yearOSratewas72%(95%CI42–88).Weconcludethatimatinibtherapysub-Saharan
African CML patients is very promising and has favorably changed the prognosis for black African patients with CML.
1.Introduction
Chronic myeloid leukemia (CML) is a clonal myelopro-
liferative disorder of a pluripotent stem cell1 ﬁrst described
by John Hughes Bennett in 1845. It was the ﬁrst malignancy
that had a speciﬁc chromosomal abnormality uniquely
linked to it after the discovery of a minute chromosome
now known as the Philadelphia (Ph) chromosome, later
deﬁned to result from a t(9;22) reciprocal chromosomal
translocation [1]. Of critical importance was the demon-
stration that this translocation involved the ABL1 (Abelson)
proto-oncogene in chromosome 9 and the BCR (breakpoint
cluster region) gene in chromosome 22 [2]. Clinically, CML
progressesthroughthreedistinctphases:achronicphasethat
is easily controlled by conventional chemotherapy followed
by an ill-deﬁned unstable accelerated phase, leading to a
terminal blastic phase. The latter phase resembles acute
leukemia and is highly refractory to chemotherapy with
under 20% response rate and a median survival of 3–6
months [3]. Since then, a constant stream of clinical and
basic advances has made CML one of the most extensively
studied human malignancies. Imatinib mesylate (STI571,
Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) is a
selective Bcr-Abl protein tyrosine kinase inhibitor against c-
abl,bcr/abl,c-kit,andplatelet-derivedgrowthfactorreceptor
(PDGF-R). Imatinib mesylate has demonstrated signiﬁcant
activity in all phases of Philadelphia chromosome- (Ph-)
positive chronic myeloid leukemia (CML) [4]. Within the
past 5 years, a promising new therapy has become available
for the treatment of African patients with CML with the ﬁrst
introduction of Bcr-Abl tyrosine kinase inhibitor imatinib
(formerly STI571) into clinical trials. With the availability of
free imatinib mesylate in resource-poor countries through
donation from the Glivec International Patient-Assistance
program (GIPAP); this drug has also become the ﬁrst-line
therapy for CML in Cote d’Ivoire a great relief for patients in
resource-limited countries. This paper describes the results
for patients with newly diagnosed CML in chronic phase.2 Advances in Hematology
2.MaterialsandMethods
Patients. The national division of Haematology teaching
Hospital of Yopougon-Abidjan (CHUY) is the referral centre
for diagnosis and treatment of haematology disorders in
Cˆ ote d’Ivoire. We performed a prospective trial of imatinib
mesylate for patients with newly diagnosed African chronic
myelogenous leukemia (CML). All patients treated for CML
at CHUY have been registered prospectively in our leukemic
database, established in 2005. In all patients, the diagnosis
of CML was conﬁrmed prior to imatinib mesylate treatment
by morphologic review of peripheral blood (PB) and bone
marrow and by documentation of the presence of the BCR-
ABL translocation by conventional metaphase cytogenetic
analysis or molecular studies. Chronic phase was deﬁned as
fulﬁlling all the following criteria: (a) peripheral or marrow
blasts less than 15%, (b) peripheral or marrow blasts +
promyelocytes less than 30%, (c) peripheral or marrow
basophils less than 20%, and (d) platelets equal to or greater
than 100·109/L [5]. The occurrence of additional karyotypic
abnormalitieswasnotconsideredacriterionforacceleration.
The Sokal prognostic score at diagnosis was calculated as
described elsewhere [6]. All of the patients gave written
informed consent to participate in the studies.
Treatment with Imatinib. In general all patients received
imatinib at a oral dose of 400mg daily; no concomitant
chemotherapy was administered other than short courses
of hydroxyurea when deemed necessary. Imatinib dosage
was adjusted depending on tolerance and response. Imatinib
box was delivered to CML patients at the hospital under
medical supervision in a full compliance according to GIPAP
programs requirements monthly by returning the empty
plaques before the next subsidy. Doses were reduced in
the presence of grade 3-4 thrombocytopenia or grade 3-
4 neutropenia. Wherever possible the dose was maintained
above 300 mg/day. The study was approved by the insti-
tutional ethics committee and conducted according to the
Declaration of Helsinki. Patients with accelerate and blastic
phase were not included in our studies.
Follow-uppatientsweretreatedaslongastheycontinued
to respond. They were assessed for response to treatment
by weekly physical examination, full blood count, and
biochemistry for the ﬁrst 6-weeks and at 6 week intervals
thereafter; bone marrow morphology and cytogenetic were
assessed every 3 months. Cytogenetic analysis, using the G-
banding technique, was performed all patients before the
initiation of therapy and every 3 months during the course
of therapy. Cytogenetic response was determined based on
the percentage of Ph-positive metaphases.
2.1. Response Criteria. Cytogenetic responses were classiﬁed
in accordance with standard UK Medical Research Council
practice as complete (0% Ph+ metaphases), partial (1–35%
Ph+ metaphases), A major cytogenetic response included
complete and partial cytogenetic responses (Ph-positive less
than35%),minor(36–95%Ph+)andnoresponse(96–100%
Ph+).
End points sustained hematologic and cytogenetic
response. Hematologic response was deﬁned as described
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Figure 1: Overall survival of patients with CML imatinib mesylate
therapy.
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Figure 2: Even-free survival of patients with CML imatinib
mesylate therapy.
previously. Primary hematologic resistance was considered if
patients failed to achieve any hematologic response.
2.2. Adverse Events. Adverse events were graded using the
NationalCancerInstitute/NationalInstitutesofHealthCom-
mon Toxicity Criteria, Version 2.0. Grade 3/4 hematologic
toxicity was assessed regarding the time of ﬁrst occurrence
and duration.
2.3. Statistical Analysis. Survival analysis was performed
using the Kaplan-Meier method. Duration of hematologic
or MCR was assessed for responding patients as the time
from the ﬁrst observation of response to disease recurrence,
death, or last visit. Overall survival was calculated from
treatment initiation to death from any cause or at the date of
the last visit. Event Free Survival (EFS) was calculated from
diagnosis to the ﬁrst observation of disease progression or
deathorinterruptedtreatmentfortoxicities.Forcomparison
of cohorts, the Mann-Whitney test was employed.Advances in Hematology 3
3. Results
Between May 2005 and September 2009, 42 patients with
CML were treated with imatinib mesylate (Gleevec).
The clinical characteristics of all patients are shown in
Table 1. The median age of patients was 40 years (range 16–
69 years), and 26 patients (62%) were males. The median
time from diagnosis was 1.5 years (0.1–7). Risk group
(Sokal) stratiﬁcation for patients with evaluable data was as
follows: low risk 16.6%, intermediate risk 44.5%, and high
risk 38.9%. Before treatment there were 17 patients (41%)
with additional chromosomal abnormalities (Table 2). The
overallmedianfollowuptimewas32months(range:7.6–113
months).
3.1. Response, Duration of Response, and Survival. The
median time from diagnosis to start Imatinib was relatively
long, 9.41 months (range: 0.2–25 months). Overall rates
of hematological and cytogenetic responses to imatinib
mesylate therapy are shown in Table 3. The median follow-
up of the study group was 32 months (range: 7.6–113
months).
TheCHRrateinourstudygroupwas76%.Amajorcyto-
genetic response was noted in 19 patients (45%): complete
in 7 (17%) and partial in 12 (29%). Complete cytogenetic
response was achieved in only 1 patient (14%) 3 months
of therapy, in 2 patients (29%) 6 months, and 4 patients
(57%) 9 months. There were no signiﬁcant diﬀerences
in the incidence of major cytogenetic response by known
prognostic factors (age, splenomegaly, sex, leukocytosis,
thrombocytosis, blasts, and Sokal score). However, during
clinical follow-up, patients with additional abnormalities
showed signiﬁcant lower CHR (59% versus 88%) (P = .035)
and MCyR (24% versus 60%) (P = .043) as compared
to those with only Ph chromosome (Table 4). But there
was no signiﬁcant correlation between CCyR in the two
situations. Moreover, there was no signiﬁcant correlation
between cytogenetic and hematologic response and the delay
oftreatment.ThemediantimetoCHRwas8months (range:
0.4–25 month), and the median time to cytogenetic response
was 16 months (range: 0.1–36 month). The projected 5-year
overallsurvivalratewas72%(95%CI:42–88)(Figure 1).The
projected2-yearsEFSwas60%(95%CI:35–77%)(Figure 2).
This projected 5-years overall survival rate by cytogenetic
proﬁle was 78% (95%CI: 38–94%) with Ph+ alone versus
62% (95%CI; 14–89%) with Ph+ with additional chromo-
somal abnormalities. Side eﬀects of imatinib mesylate in
this study were similar to those reported previously for
the entire imatinib mesylate treatment study. The severe
(grade 3-4) toxic eﬀects experienced are shown in Table 5.
At a median follow-up duration of at least 32 months
(range: 7.6–113 months) Twenty-three (55%) were alive in
chronic phase and are still taking imatinib mesylate, and 10
patients(24%)died.Eightdiedafterdevelopingblasticphase
disease; 2 died from pulmonary tuberculosis associated with
accelerated-phase disease. Five patients stopped therapy 3
of cutaneous toxicity, 1 with neurological depression, and 1
with cardiac symptoms. No patients died in chronic phase
from imatinib mesylate-related complication. Four patients
Table 1: Pretreatment characteristics of the study population of 42
patients with CML.
Variable no.
Gender, n. (%)
Male 26
Female 16
Age (yrs) (median range) 40 (16–69)
Time from diagnosis (yr) (median range) 1.5 (0.1–7)
ECOG at diagnosis
0-1 25 (59)
2-3 17 (41)
Hepatomegaly n (%) 15 (36)
Splenomegaly, n (%)
0cm 4 (10)
1–9cm bcma 25 (59)
≥10cm bcm 13 (31)
Peripheral blood (median range)
Hemoglobin level (g/dL) 10.2 (5.7–13.7)
Platelet count (109/L) 331.5 (132–1992)
Leukocyte count (109/L) 211.7 (50–854)
Basophils in PB (%) 0 (0–6)
Blasts in PB (%) 1.9 (1–8)
Blasts in BM (%) 1 (0–4)
Ph status before therapy, n (%)
Ph1+ 25 (59)
Additional chromosomal abnormalities 17 (41)
Sokal score
Low risk. n. (%) 11 (16.6)
Intermediate risk n. (%) 16 (44.5)
High risk n. (%) 15 (38.9)
Cma: centimeters below the costal margin.
developed accelerated phase and received dose escalated
600mg daily of imatinib mesylate.
4. Discussion
Our study of patients with newly diagnosed CML chronic-
phase Ph+ is unique in sub-Saharan Africa. To our knowl-
edge there are few data regarding imatinib therapy for sub-
Saharian African patients with Ph + leukemia [7]. Regarding
the clinical and biological feature, CML of black African
patients seems to be generally aggressive. First, the median
age of patients with CML in Cˆ ote d’Ivoire and other African
countries with similar demographic pattern is over 40 years
[7–9]. Fleming et al. reported that native African patients
less than 40 years suﬀer from CML more than any other
group in the world; the diﬀerential age incidence pattern
of CML is believed to be due to the age distribution of
African population rather than any other inherent biological
characteristics [10]. But this age seems to be lower than that
reportedinEuropeandUnitedstates[11].Second,wefound,
high incidence of additional cytogenetic abnormalities. So4 Advances in Hematology
Table 2: Detailed cytogenetic response of 17 CML patients with
additional chromosomal abnormalities prior to imatinib therapy.
Patient
no. Cytogenetic analysis
(1) 46,XX, t(9;22)(q34;q11)[11] / 45-46,idem, dup
(14)(q22;q32)[5]
(2) 46, XY, t(9; 22) (q34; q11) [20]/46, idem, del (12) (p12)[12]
(3) 46,XX, t(9;22)(q34;q11)[9]/47,XX, idem,+8[11]
(4) 46,XY, t(3;13)(p25;q14),t(9;22)(q34;q11)[28]/52,
idem,+6,+7,+8,+19,+21,+der(22),t(9;22)(q34;q11)[12]
(5) 46, XY, del(3)(p12p14), t(9;22)(q34;q11)[5]/46,XY, t(9 ;22)
 
q34;q11)[31]
(6)
46, XY, t(9;10;22)(q34;p14;q11)[15]/ 46,XY, t(9;10;22)
(q34;p14;q11),del(13)(q21)[2]/
47, XY, t(9;10;22)(q34;p14;q11),+mar1[3]
(7) 46,XX, t(9;22)(q34;q12)[29] / 46,idem, t(4;11)(q13;p12)[11]
(8) 46,XY,t(9;22)(q34;q11)[14]/47,idem,+8[11]
(9) 46,XX,t(9;22)(q34;q11),add(13)(p11),add(20)(p13)[23]
(10)
46, XY, t(9;22)
([16]/46,idem,der(12)t(12;14)(q10;q10),add(13)(p11.2),
-14, -mar[4]
(11) 46, XY, t(9;22)[12]/46, XY, der(9)t(9;22),der(22q)[7]/ 47,
XY, t(9;22), der(22)t(9;22)[11]
(12) 46, XY, t(9;22),-17,add(19)(q13.4),- mar[19]/46,XY, t(9;22),
-17,add(19)(q13.4)[11]
(14) 47 XY,+8,t(9;22)(q34;q11)[3] /46,XY,t(9;22)(q34;q11)[23]
(15) 46, XY,t(9;22)[8]/46,idem,add(1)(p36.3)[12]
(16) 46, XY, add(2)(p25),t(9;22)(q34;q11)[6]
/46,XY,t(9;22)(q34;q11)[43]
(17) 46,XY,t(2;9;22)(q15;q34;d11)[28]
Table 3: Hematologic and cytogenetic response.
Characteristics n. (%) (n = 42)
Hematologic remission
Complete 32 (76)
Partial 10 (24)
Cytogenetic response 33 (79)
Major (Ph ≤ 35%) 19 (45)
Complete (Ph+ = 0%) 7 (17)
Partial (Ph+ = 1%–35%) 12 (28)
Minor (Ph+ 36% –95%) 14 (33)
Minimal/no (Ph+ >95%) 12 (29)
over 41% of additional chromosomal abnormalities were
found with high incidence of intermediate and high risk
of Sokal staging system length in part with the long mean
delay from diagnosis 17 months. The high incidence rate of
additional chromosomal abnormalities seems particular in
African CML leading to the poor prognostic of our patients.
In those studies the percentage of additional chromosome
abnormalities length was 15% to 25% for patients in chronic
phase [12–14].
With the overall median follow-up time of 32 months
(range: 7.6–113 months), we found 76% of CHR rate and
Table 4: Hematologic and cytogenetic response according to Ph+
alone or additional chromosomal abnormalities.
Characteristics Ph+ alone
Ph+ with
additional
abnormalities
P
n. (%) (n = 25) n. (%)
(n = 17)
CHR 22 (88) 10 (59) .0357
MCyR 15 (60) 04 (24) .043
CCyR 6 (24) 1( 6 ) .210
CHR: complete hematologic response; MCyR: major cytogenetic response;
CCY: complete cytogenetic response.
Table 5: Incidence of grade 3-4 side eﬀects with imatinib mesylate
therapy (n=4 2 ).
Toxicity No. (%) with grades
3-4 toxicity
Non Hematologic toxicities
Bone or Joint aches 11 (26)
Others(a) 10 (24)
Skins rash 3( 7 )
Nausea 2( 5 )
Diarrhea 2( 5 )
Muscle cramps 2( 5 )
Hematologic toxicities
Granulocytopenia < 1·109/liter 14 (33)
Thrombocytopenia <50·109/liter 10 (24)
Anemia < 8g / dl i t e r 5 (12)
(a)2 withfever, 1withneurologicaldepression symptoms,and1with cardiac
symptoms, fatigue 6.
79% had cytogenetic response, which was major in 45%
and complete in only 17%. Thus, the results with imatinib
mesylate therapy continue to be positive with longer follow-
up. This result is lower than that of the reported case of
literature. The high rate of RCC was reported by Kantarjian
et al. and the IRIS study 81% and 86%,respectively [15, 16].
The study of Muheez et al. in Nigeria reported 35% of RCC
[7]. But in these several studies patients had previously been
treated by INF-α or other chemotherapy as the ﬁrst-line
treatment. Overall, 80% of newly diagnosed patients with
CML in chronic phase would be expected to achieve CCR
with imatinib [17].
The median time from diagnosis to commencement of
Imatinib was relatively long, t 9.41 months (range: 0.2–25
months), and it is known that this can worsen the prognosis
and reduce the probability of response. Our results suggest
that there is a small subset of patients whose leukemic cells
remain sensitive to imatinib therapy despite the presence of
additional chromosome abnormalities. On the other hand,
we observed a larger group of patients (12 of 42 patients,
29%) who did not attain a CR with STI571 therapy. This
result seems to be high compared to those reported in
the literature computer [13, 14]. The karyotype proﬁle of
these cases tended to be more complex than the CR cases.Advances in Hematology 5
Follow-up study on the Ph no-responder CML patients
revealed that the majority of patients also failed to respond
clinically to STI571 or progressed after an initial brief
response to therapy. This can be explained by the higher
rate of additional cytogenetic chromosome abnormalities.
It appears to be a subset of patients with disease that is
refractory to a dose of 400mg/day of imatinib and who may
beneﬁt from dose escalation in the ﬁrst treatmen intent. The
results of this case can be improved by frontline therapy with
imatinib mesylate in combination with other drugs or by
high-dose imatinib mesylate therapy as previously reported
by Kantarjian et al. [17].
There were no signiﬁcant diﬀerences in the incidence
of major cytogenetic response, by known prognostic fac-
tors (age, splenomegaly, sex, leukocytosis, thrombocytosis,
blasts,and Sokal systems scoring) perhaps due to the short
eﬀectiveness of our study population. In the large ran-
domized study, found the signiﬁcant correlation between
these classical prognostics parameters with the cytogenetic
response rate has been [12, 14].
Previous experience has led to estimated yearly mortality
rates of 10%–15% for patients in chronic-phase CML that
hadfailedtorespondorhadrelapsedduringtherapy[18,19].
In our study our mortality rates were estimated as 24%. This
mortality rate seems to be very high.
Imatinib mesylate therapy is now the new standard of
care for patients with chronic-phase CML. Combinations of
imatinib mesylate with IFNα, cytarabine, homoharringto-
nine, decitabine, or other compounds hopefully will further
improve the complete cytogenetic and molecular response
rates and thus the long-term prognosis for patients with
additional chromosome abnormalities [20].
Nonetheless, the projected 5-years overall survival rate of
72% (95%CI, 42–88) seems to be impressive for an African
population of patients. The extended IRIS study has recently
reported a 5-year overall survival estimated as 89% [16]
and several studies have demonstrated signiﬁcant survival
diﬀerences based on the Sokal and/or Hasford risk groups
at diagnosis [21–24]. This overall survival in this study was
better than that of the reported case of our previous study
of alpha-interferon with the projected 5-year overall survival
rate of 50% [25].
Based on this advantage survival, this work has shown
thattheoutcomeofimatinibtherapyfornewlydiagnosePh+
CML chronic phase in the sub-Saharan African country of
Cˆ o t ed ’ I v o i r ei sn of a rd i ﬀerent from reports in the Western
populations.Weconcludethatimatinibtherapysub-Saharan
African CML patients is very promising despite the high
incidence of additional chromosome abnormalities, with
the additional advantage of oral availability and tolerability.
Imatinib has favorably changed the prognosis for black
African patients with CML.
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